Dragonhead (Dracocephalum moldavica L.): A Comprehensive Reference
1. Identity, Nomenclature, and Botanical Description
Scientific and Common Names
Dracocephalum moldavica L. — the Moldavian dragonhead — is an annual herbaceous plant. Its genus name derives from the Greek for "dragon's head," a reference to the shape of its flowers. In Chinese it is known as Xiang qinglan, and it also bears the names Moldavian balm, Yixin Badi Ran Gibuya, Toronjil-azul, Toronjil chino, Badarshoo, and Baeiranjibo, among others. In Mexican traditional medicine it is known as "toronjil chino, toronjil extranjero, or toronjil azul."
Taxonomy
Dracocephalum moldavica is an aromatic herb in the Lamiaceae family. The genus Dracocephalum comprises approximately 60 species of herbs that thrive in temperate regions of Asia, often found in high mountainous areas or semiarid regions. The first formal botanical description of D. moldavica was by Linnaeus in Species Plantarum 2:595, 1753.
Morphology
Dragonhead is a hardy annual plant approximately 2 ft tall, with aromatic, balm-scented green foliage. The herb grows as an upright annual, usually 30–50 cm tall, with square stems (a mint family hallmark) and paired opposite, lanceolate leaves. Dracocephalum moldavica is often mistaken for Melissa officinalis.
Native Range and Distribution
Although there is no precise accounting of its native range, D. moldavica is known to be native to the temperate climate of Asia, including China (Gansu, Hebei, Heilongjiang, Henan, Jilin, Liaoning, Inner Mongolia, Shaanxi, Xinjiang, and Shanxi provinces), Russia (Primorsky Krai; eastern and western Siberia), Tajikistan, and Turkmenistan. It has been naturalized in Eastern and Central Europe, North Africa, China, and the northeastern United States. It also grows in Egypt, Mongolia, and the Himalayas, at altitudes of up to 2700–3100 m above sea level.
Common Forms and Preparations
This plant with its citrus-like flavor is extensively used as a spice and for composition of teas, and is used in food aromatization, the perfumery industry, alcoholic drinks, soaps, and detergents. Apart from being used as a medicinal and spice plant, it is grown as a honey-bearing plant and cultivated in gardens as an ornamental. The seed is a good source of fatty oil rich in unsaturated fatty acids, principally linolenic and linoleic acids. Commercial supplement preparations include standardized aqueous powdered extracts (spray-dried onto a maltodextrin carrier), whole dried herb, herbal teas, essential oils, and seed oil. The leaves have been used to make snacks and bread, and the seeds have been used to make snacks and tea.
2. Traditional and Historical Use
Central and East Asia (Uyghur and Mongolian Medicine)
Dracocephalum moldavica L. is a traditional Uyghur medicine with the Uyghur name BadiRanjibuya, used in Xinjiang and included in the Uyghur classical medical book "Aricanon." More than 800 years of clinical practice has proven that it is effective in the treatment of cardiovascular disease (CVD). There are nine prescriptions for the treatment of CVD in the "Medical Standards of the Ministry of Health of the People's Republic of China Uyghur Medicine Volume," and three contain D. moldavica. The traditional Mongolian medicine uses D. moldavica as a tea (non-Camellia tea) for the prevention and treatment of coronary heart disease, hypertension, atherosclerosis, and other diseases. The plant has been used for centuries by the Uyghur people in their daily lives, consumed in the same way as tea.
Chinese Traditional Medicine
Known as Xiang-qing-lan in Chinese, it is a traditional folk medicine commonly used by Mongolian and Xinjiang Uyghur communities. It has the effects of purging liver fire, clearing stomach heat, and hemostasis; it is used for treating insufficient heart and blood, weakened brain function, and spirit disease. It is mainly used in clinical treatment of coronary heart disease, hypertension, angina pectoris, arteriosclerosis, and myocardial ischemia.
European Folk Medicine
Moldavian dragonhead was known in Europe since the sixteenth century, first as Melissa moldavica, and originated from southern Siberia. It has been traditionally used to treat headache, gastric, hepatic, and cardiovascular disorders, and also as a food additive.
Mexican Traditional Medicine
In Mexico, D. moldavica has been adapted to the central region of the country, where it is systematically cultivated year-round. In Mexican traditional medicine it is known as "toronjil chino, toronjil extranjero, or toronjil azul" and is used as a mild tranquilizer remedy and as a sedative agent. It also forms part of an herbal tea combination — alongside species such as Agastache mexicana, Cinnamonum sp., and others — used to treat nervios, a folk illness recognized in Mexican traditional medical systems.
Traditional Indications Across Cultures
The traditional medicinal uses of Dracocephalum species encompass the treatment of respiratory diseases, colds and fever, gastrointestinal disorders, liver and gallbladder ailments, musculoskeletal conditions, cardiovascular diseases, diabetes, gynecological and urological disorders, as well as ailments of the ears, throat, mouth, eyes, and various dermatological conditions. In high-altitude regions it has been used in folk medicine to treat, principally, heart disease, blood pressure, angina, atherosclerosis, neuralgia, migraine, headache, and toothache.
3. Phytochemistry: Key Constituents and Active Compounds
Overall Chemical Diversity
Approximately 154 compounds have been isolated and identified from the aerial parts of D. moldavica, including flavonoids, terpenoids, lignans, phenylpropanoids, phenols, glycosides, and polysaccharides. In addition to essential oils, the plant contains flavonoids, terpenoids, lignans, phenylpropanoids, phenols, glycosides, polysaccharides, protein, amino acids, and minerals such as iron, copper, manganese, and strontium.
Essential Oil
Geranyl acetate (30.4–43.2%), geraniol (15.37–29.69%), geranial (12.83–23.29%), and neral (8.68–17.33%) are the main essential oil constituents of dragonhead. Citral is a major component of the oil (30–45%). In some geographical origins, up to 90% of the oil consists of oxygenated acyclic monoterpenes — geraniol, geranial, neral, nerol, and geranyl acetate.
Flavonoids and Phenolic Acids
The flavonoid profile of Dracocephalum species is dominated by luteolin and apigenin derivatives, supplemented by mono-, di-, tri-, tetra-, and pentamethylated flavones. The predominant phenolic acids are chlorogenic acid, coumaric acid, rosmarinic acid, and their derivatives. In the dried whole plant, identified flavonoids include apigenin, luteolin, kaempferol, isorhamnetin, tilianin, agastachoside, acacetin-glycoside, and syringaresinol. The aerial parts contain polyphenols such as rosmarinic and caffeic acids and flavonoids including apigenin, luteolin, and quercetin. Rosmarinic acid has been identified as the main polyphenolic compound, with amounts ranging between 5.337 ± 0.0411 and 6.320 ± 0.0535 mg/mL in cultivar extracts.
Seed Lipids
The seed is a rich source of omega-3 fatty acids, with a particularly high content (59.4%) of linolenic acid after processing volatile oils. Seed oil is rich in unsaturated fatty acids (about 90%), principally linolenic and linoleic acids (about 60% and 20%, respectively).
Polysaccharides
The polysaccharides of D. moldavica have anti-complement activity.
4. Established and Proposed Mechanisms of Action
Antioxidant Mechanisms
The total flavonoids of D. moldavica show remarkable scavenging effects against 1,1-diphenyl-2-picrylhydrazyl (DPPH), hydroxyl, and superoxide anion radicals in vitro. The ethyl acetate fraction from D. moldavica ethanol extract ameliorates oxidative cardiotoxicity via antiapoptotic and antioxidant mechanisms.
Cardiovascular Mechanisms
Research indicates that D. moldavica flavonoids have multicomponent, multitarget, and multichannel characteristics in the treatment of cardiovascular disease. The mechanism may be associated with the NOX-4/ROS/p38 MAPK signalling pathway. Pharmacological experiments have shown that the flavonoid extract has antioxidative effects, scavenges oxygen free radicals, and provides myocardial protection.
Anti-inflammatory Mechanisms
Network pharmacology analysis has revealed that the active ingredients in D. moldavica extract — including luteolin, rosmarinic acid, oleanolic acid, ursolic acid, apigenin, acacetin, kaempferol, and isorhamnetin — are closely associated with anti-inflammatory activity via signalling pathways including NF-κB, IL-17, TNF, and Toll-like receptor pathways.
Antimicrobial Mechanisms
Against MRSA isolates, the ethyl acetate fraction of D. moldavica ethanol extract significantly increased the release of phosphate ions (p < 0.05), with significant differences in phosphate ion leakage observed within 3 hours, suggesting cell membrane disruption. The EtOAc fraction disrupted 24-hour biofilm, caused cell membrane damage, and produced irregular cell shape.
Sedative and CNS Mechanisms
The aqueous extract of D. moldavica aerial parts induced sedative actions and a general inhibition of CNS activity observed by decreases in general activity, motor coordination, and exploration behavior in animal studies. The pleasant lemon-like smell has been attributed to relaxation properties; analysis of its essential oil has revealed the presence of geraniol and citral, which could account for its tranquilizing properties.
Anti-aging / Cellular Longevity Pathways
DracoBelle Nu (a standardized dragonhead extract) has been proposed to mimic the effects of caloric restriction — a mechanism mediated by AMPK and FOXO activation — leading to improved cellular defence, oxidative stress resistance, cell detoxification, and repair. In bioassay trials, the plant source was reported to increase FOXO and AMPK activity by three- and fourfold, respectively.
5. Scientific Evidence by Area of Use
5.1 Cardiovascular Protection
Preclinical (in vitro / animal) evidence: A study evaluated antioxidative and cardioprotective effects of total flavonoids from D. moldavica (DML). The total flavonoids showed remarkable scavenging effects against DPPH, hydroxyl, and superoxide anion radicals in vitro. In an improved Langendorff retrograde perfusion model, total flavonoid (5 μg/mL) pretreatment improved heart rate and coronary flow, raised left ventricular developed pressure, and decreased creatine kinase and lactate dehydrogenase levels in coronary flow. Recent pharmacological research has indicated that D. moldavica exhibits protective effects on myocardial ischemia and cerebral ischemia, vasodilative effects, improvement in vascular dementia, and anti-atherosclerosis activity.
Clinical context: The effectiveness of D. moldavica L. in the treatment of CVD has been documented in clinical practice in the Xinjiang Uyghur region. However, the mechanism by which it treats CVD has not been systematically determined. Most studies have focused on pharmacodynamics, and there have not been systematic analyses of the mechanism by which D. moldavica treats CVD, including targets, molecular mechanisms, and interactions between components — areas that need further study. Rigorously designed randomized controlled trials in general populations remain absent from the published literature.
5.2 Antioxidant Activity
In vitro evidence: Numerous studies have demonstrated that D. moldavica possesses antioxidative properties. Polyphenols have been identified and quantified using spectrophotometric methods and LC-MS analysis, and antioxidant capacities have been assessed using DPPH and ferric reducing antioxidant power (FRAP) methods. Evidence at this level is consistent across multiple studies; translation to clinically meaningful human antioxidant outcomes has not been established through randomized controlled trials.
5.3 Sedative, Anxiolytic, and Antidepressant Effects
Animal evidence: A published study evaluated the sedative, anxiolytic-like, and antidepressant-like effects of the aqueous extract of aerial parts of D. moldavica in behavioral models in mice. General toxic effects were also evaluated and chemical analysis was performed. The aqueous extract induced sedative actions and a general inhibition of CNS activity observed by decreases in animals' general activity, motor coordination, and exploration behavior. This finding supports the traditional use of D. moldavica as a sedative and tranquilizer remedy in Mexican traditional medicine.
Evidence strength: All neuropharmacological evidence is from animal behavioral models. No human clinical trials for sedative or anxiolytic outcomes have been published in peer-reviewed literature.
5.4 Analgesic / Antinociceptive Effects
Animal evidence: Essential oil administration at 5–20 mg/kg produced a significant antinociceptive effect in the formalin test, and at 20 mg/kg in the acetic acid-induced writhing test, in animal models. The essential oil failed to demonstrate any significant influence on hot-plate reaction latency. These results suggest that D. moldavica essential oil possesses analgesic properties that support folk medicinal use. Documented traditional use includes analgesic activity, with rosmarinic acid identified as a main compound responsible for the analgesic effect. Evidence is limited to preclinical models.
5.5 Antimicrobial and Antifungal Activity
In vitro evidence: A study investigated the antimicrobial effects of D. moldavica extracts against clinical isolates of Staphylococcus aureus. The minimal inhibitory concentration (MIC) for 50% and 90% of S. aureus isolates (MIC50 and MIC90) of the ethyl acetate fraction were 780 and 1,065 μg/mL, respectively. The EtOAc fraction disrupted 24-hour biofilm, caused cell membrane damage, and produced irregular cell shape. However, no antimicrobial activity against Gram-negative bacteria and fungi tested was observed at concentrations up to 250 mg/mL. These are in vitro findings; no human clinical trials for antimicrobial outcomes have been published.
5.6 Chronic Mountain Sickness (Altitude Sickness)
Animal evidence: Dracocephalum moldavica L. is a traditional Uyghur medicine with cardiac activities, but until recently no reports were available on its use against chronic mountain sickness (CMS). A study was designed to explore the treatment efficacy of D. moldavica on a CMS rat model. Eighty of 100 Sprague-Dawley rats were bred in a simulated high altitude environment; water and alcohol extracts of D. moldavica were prepared and tested. Results showed that IL-6, CRP, MDA, SOD, and GSH-Px participate in and mediate the formation of CMS, and D. moldavica was found to possess noticeable effects on CMS. DML also appears to reduce pulmonary artery pressure and have anti-oxidation effects, which may play a role in its prevention of altitude sickness. Further preclinical and clinical studies with larger sample sizes are recommended.
5.7 Anticancer / Cytotoxic Activity
In vitro evidence: In one study, 13 phenolic constituents of four different compound classes were isolated from the aerial parts of the Moldavian dragonhead. All compounds were tested for their apoptotic effect on myeloma (KMS-12-PE) and AML (Molm-13) cells, with the highest activity observed for the flavone and flavonol derivatives. Diosmetin was effective against myeloma cell line KMS-12-PE, while cirsimaritin and xanthomicrol showed pronounced effects on AML cell line Molm-13 at lower concentrations and were identified as novel FLT3 inhibitors. At concentrations ranging from 10 to 2.5 µM, cirsimaritin inhibited proliferation to an extent of 88–72% in AML cells, while xanthomicrol showed an inhibition of up to 93% (and of still 84% at a concentration of 2.5 µM). These anticancer effects on AML cells at reasonably low concentrations are promising and warrant further testing. All evidence is in vitro only; no clinical trials exist.
5.8 Hypolipidemic Activity
Preclinical evidence: The mechanism underlying the lipid accumulation-reducing effects of D. moldavica ethanol extract was determined using in vitro experiments and four polar fractions were screened. The effect of the ethyl acetate fraction on lowering blood lipid was confirmed in vivo in rats. Network pharmacological and serum pharmacochemistry analyses showed that apigenin, luteolin, and naringenin existed in prototype form in the drug-containing serum of rats. These findings are from animal and cell-based models only.
5.9 Gut and Liver Effects
Preclinical evidence: Dracocephalum moldavica extract, recognized as a common traditional Chinese medicine, has been demonstrated to possess antioxidative, anti-inflammatory, and antibacterial properties. In a dextran sulfate sodium-induced chronic colitis rat model, DML extract ameliorated ulcerative colitis by improving disease activity index, weight loss, colon length, and histological scoring. DML extract administration also enhanced the count of Lactobacillus and reduced the count of Romboutsia. The total flavonoids of D. moldavica have been demonstrated to possess anti-inflammatory, antioxidant, and insulin resistance-alleviating biological activities; the same research group demonstrated that the total flavonoids can exert anti-colitis effects through regulating the gut microbiota and TLR4/NF-κB pathway. All evidence is from animal models.
5.10 Skin Anti-Aging and Collagen Synthesis
In vitro evidence: In vitro studies have shown that a D. moldavica extract stimulates genes crucial for skin structure. Investigation further revealed that the extract increased the level of collagen gene expression significantly, resulting in increased collagen content in aged skin tissues.
Human clinical evidence: A double-masked, randomized, placebo-controlled clinical trial in female volunteers demonstrated that oral supplementation with the extract significantly improves skin hydration and increases dermal and full-skin thickness. In the more recent published trial, a total of 103 subjects (aged 35–65 years) consumed 100 mg of the D. moldavica extract per day (or 100 mg of maltodextrin as the control) for 12 weeks. The extract was considered well-tolerated, and no adverse effects were reported during the observation period. An earlier pilot study used a daily dosage of 200 mg for two months. This proprietary extract (DracoBelle Nu sd) may enhance collagen production, hydration, and skin thickness, according to published research funded by Mibelle Biochemistry. Importantly, these clinical studies were industry-funded and used a proprietary extract; independent replication has not yet been published.
6. Body Systems and Health Areas of Association
- Cardiovascular system: Clinical use in coronary heart disease, hypertension, angina pectoris, arteriosclerosis, and myocardial ischemia.
- Central nervous system: Sedative, analgesic, and antidepressant properties have been demonstrated in preclinical models.
- Gastrointestinal system: Traditionally used to treat gastric and hepatic disorders.
- Integumentary system (skin): The anti-aging potential of the extract has been investigated, with in vitro studies showing stimulation of genes crucial for skin structure and a clinical trial demonstrating improvements in skin hydration and dermal thickness.
- Immune / anti-infective system: Antimicrobial and antifungal activities have been confirmed in vitro.
- Respiratory / altitude physiology: Active components of D. moldavica can significantly improve hypoxia, decrease pulmonary artery pressure, and improve cardiac pathological state in preclinical models.
- Hematological / oncological (preclinical): Studies reveal chemopreventive effects of several flavonoids against multiple myeloma and acute myeloid leukemia in vitro.
- Metabolic / hepatic: Total flavonoids have demonstrated anti-inflammatory, antioxidant, and insulin resistance-alleviating biological activities in preclinical models.
7. Dosage Forms and Dosages Reported in Studies
No universally standardized clinical dosage for D. moldavica as a botanical supplement has been established across regulatory pharmacopoeias. The following dosages appear only in the specific research contexts identified:
- Standardized aqueous extract (DracoBelle Nu / DracoBelle Nu sd), oral, skin aging: 103 subjects consumed 100 mg of the extract per day for 12 weeks in the most recent placebo-controlled clinical trial. An earlier clinical study reported a daily dosage of 200 mg for two months.
- Total flavonoids, intravenous/isolated heart preparation, cardioprotection: 5 μg/mL total flavonoid pretreatment was used in the Langendorff retrograde perfusion model.
- Essential oil, antinociception, animal: Administration at 5–20 mg/kg produced significant antinociceptive effects in the formalin test and at 20 mg/kg in the acetic acid-induced writhing test.
- Antimicrobial (in vitro): The MIC50 and MIC90 of the EtOAc fraction against S. aureus were 780 and 1,065 μg/mL, respectively.
- Acute toxicity (mice, gavage): Total flavonoid extract given to mice by gavage at the maximum dose of 19.2 g/kg/day (equivalent to 711 times the proposed clinical dose) in a day did not produce significant acute toxicity during the observation period.
- Subchronic toxicity (rats, oral): In a 90-day repeated-dose oral toxicity study in 80 rats (40 male/40 female) at dose levels of 0, 250, 500, and 1,000 mg/kg bw/day, no treatment-related mortality or clinical signs of toxicity were observed in accordance with OECD guidelines.
- Intraperitoneal LD50, essential oil, mice: The intraperitoneal LD50 of the essential oil in mice was calculated to be 600 mg/kg.
8. Safety Considerations
General Toxicological Profile
Despite its long history of human consumption and use, D. moldavica has not been the subject of published comprehensive toxicological evaluations. The safety of a powdered extract (DracoBelle Nu sd) has been examined through a battery of in vitro and in vivo toxicological studies, including a bacterial reverse mutation test, an in vivo mammalian micronucleus assay in male NMRI mice, and a subchronic toxicity study in Han:Wist rats. No mutagenic activity was observed in any tested bacterial strains with or without metabolic activation, and no evidence of clastogenic or aneugenic activity was observed in the in vivo mouse micronucleus test.
Subchronic Toxicity
In the 90-day repeated-dose oral toxicity study at dose levels of 0, 250, 500, and 1,000 mg/kg bw/day, no treatment-related mortality or clinical signs of toxicity were observed, and no significant adverse effects attributable to the test item were found in any of the examined parameters in accordance with OECD guidelines.
Human Tolerability
In the 103-participant clinical trial (100 mg/day for 12 weeks), the extract was considered well-tolerated and no adverse effects were reported during the observation period.
Regulatory Status
Mibelle Biochemistry's DracoBelle Nu sd, derived from Moldavian dragonhead, has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States, following a unanimous conclusion by a qualified panel of toxicology experts who conducted a comprehensive evaluation of safety data. In the US, D. moldavica L. is included in the Old Dietary Ingredient List, a list compiled after the passage of the Dietary Supplement Health and Education Act of 1994 and developed by the American Herbal Products Association, Council for Responsible Nutrition, Natural Products Association, and United Natural Products Alliance. It is also part of the Korean positive list.
Cytotoxicity of Extracts
In vitro, the EtOAc fraction showed slight to moderate toxic effects on human epidermal keratinocyte (HaCaT) cells. This observation is relevant only to isolated high-concentration in vitro exposure and has not been replicated as a concern in the reported human tolerability studies.
Gaps in Safety Data
Future studies of D. moldavica need to pay more attention to quality control, toxicity, pharmacological mechanism, and pharmacokinetics. Formal drug interaction studies, safety data in pregnant or lactating individuals, and long-term human safety data beyond 12 weeks are not available in the published literature.
References
Go back